Because many regimens currently used to treat GI or female pelvic anaerobic infections (see also treatment of pelvic inflammatory disease) are also effective against facultative gram-negative bacilli, use of a potentially nephrotoxic aminoglycoside (to cover enteric facultative gram-negative bacilli) plus an antibiotic active against B fragilis is no longer warranted.